At TDI, we aim to bring powerful drug discovery technologies to researchers across the Tri-Institutional community. We have established productive partnerships with a range of cutting-edge technology-based organizations, including Schrödinger, Horizon, Cyclofluidic, WuXi, Charles River, XTAL Biostructures, and the New York Structural Biology Consortium. We continue to develop strategic relationships with world-class providers of tools and technologies in both the small molecule and antibody realms.
Key to TDI's success is our unique relationship with Takeda Pharmaceuticals. Under this partnership, a team of sixteen Takeda-employed Medicinal Chemists has relocated from Japan to New York City to lead drug development activities for the small molecule projects in the TDI portfolio. Takeda is an incredibly valuable partner for TDI, and their investment in the TDI vision has allowed us to leverage their global resources to perform key drug discovery and development activities. Both parties are beneficiaries of this unique partnership. In exposing Takeda chemists to a fast-paced American academic research environment, TDI is bringing value to Takeda by training their next generation of leaders. At the end of their tenure, these secondees are bringing home new insights and perspectives in drug discovery research.
As part of our partnership, Takeda also provides TDI access to a wide variety of highly valuable supporting technologies: High Throughput Organic Synthesis (HTOS), compound crystallography, ADME/ Tox (Absorption, Distribution, Metabolism, and, Excretion/ Toxicity) studies, protein expression and purification, protein crystallography studies, PK/ PD (Pharmacokinetic/Pharmacodynamic) modeling, and access to compound libraries for screening both within Takeda and at partner organizations. These additional resources enable TDI to advance projects quickly and efficiently.